/

Repligen Corporation

RGEN US

RGEN USRepligen Corporation

United States Composite

167.86

USD

-3.42

(-2.00%)

0.73EPS Dil.

224.96P/E

9.36BMarket Cap

Next Earnings

April 30

Held by Insiders

6.57%

Held by Institutions

105.60%

Short % of Float

8.74%

YTD Yield

-6.37%

3Y Yield

-27.87%

5Y Yield

180.26%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

288

289

LT Borrowings

- -

510

LT Finance Leases

134

131

127

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

7,886

8,869

10,027

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

999

978

1,111

Cash, Cash Equivalents & STI

604

631

751

Accounts Receivable, Net

120

106

124

Inventories

241

211

202

Total Current Liabilities

374

363

158

Payables & Accruals

ST Debt

288

289

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

27.95%

31.45%

-20.32%

Net Income, GAAP

38.04%

58.09%

-77.42%

Free Cash Flow

46.57%

42.29%

85.71%

Total Cash Common Dividend

- -

Total Equity

45.24%

28.62%

3.14%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

143

163

178

187

671

2022

206

208

201

187

802

2023

183

159

141

156

639

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

0.54

0.66

0.61

0.53

2.33

2022

0.85

0.90

0.73

0.88

3.35

2023

0.52

0.36

0.33

-0.46

0.75

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Anthony J. Hunt
Full Time Employees: 1,783
Sector: Healthcare
Industry: Medical Instruments & Supplies
Address: Building 1 Waltham MA United States 02453
IPO Date: Apr 29, 1986
Website: www.repligen.com
Business: Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Company News

Yahoo
a month ago
Repligen Appoints Maggie A. Pax to Board of Directors
Yahoo
a month ago
Are Repligen Corporation's (NASDAQ:RGEN) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Yahoo
a month ago
Repligen Corp CEO Anthony Hunt Sells 16,707 Shares
Zacks
2 months ago
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Yahoo
2 months ago
PBYI vs. RGEN: Which Stock Is the Better Value Option?

Company Description

CEO: Mr. Anthony J. Hunt
Full Time Employees: 1,783
Sector: Healthcare
Industry: Medical Instruments & Supplies
Address: Building 1 Waltham MA United States 02453
IPO Date: Apr 29, 1986
Website: www.repligen.com
Business: Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.